萬邦德(002082.SZ):與北京盈科瑞創新醫藥簽署戰略合作協議
格隆匯12月28日丨萬邦德(002082.SZ)公佈,根據公司醫藥大健康產業發展戰略,為增強公司中藥研發能力和藥品臨牀試驗能力,提升公司競爭力,公司於2021年12月28日與北京盈科瑞創新醫藥股份有限公司(“北京盈科瑞”)簽署《戰略合作協議》,雙方本着平等協商、優勢互補、合作共贏的原則,就藥物研發技術服務締結長期戰略合作伙伴關係,全面開展中成藥的研發合作。
公司此次與北京盈科瑞簽署《戰略合作協議》,有利於促進各方技術、產品與服務的延伸和發展,符合公司長期發展戰略,有利於增強公司的中藥研發能力,提升藥品臨牀試驗能力,同時也有利於增強公司的持續盈利能力和整體抗風險能力,符合公司發展戰略及全體股東的利益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.